Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: R. M. Rosenthal who wrote (2347)	6/2/1998 8:32:00 AM
From: GemSeeker	Read Replies (1) \| Respond to of 5736

Chromatics Color Sciences Launches New Medical Device At Sinomed Exhibition, Beijing, China NEW YORK, June 2 /PRNewswire/ -- Chromatics Color Sciences International, Inc. (Nasdaq: CCSI) today announced that it will be launching its new device for non-invasive monitoring of bilirubin infant jaundice, the Colormate(TM) TLc-BiliTest(TM), in China at the SINOMED '98 Exhibition, the 7th China International Medical Equipment and Facilities Exhibition, from June 9 to June 12 at the China International Exhibition Centre in Beijing, People's Republic of China. The SINOMED Exhibition expects over 80,000 attendees and is the only official International Medical Exhibition hosted by the Ministry of Health, People's Republic of China and The China Council for the Promotion of International Trade (CCPIT). Following the Exhibition, representatives from the Company's Medical Advisory Board will be presenting the Colormate TLc-BiliTest at the Beijing Children's Hospital and the Beijing Obstetrics and Gynecology Hospital on June 15 and 16, 1998 respectively. Chromatics Color Sciences is in the business of color science and has developed technologies and intellectual properties which it believes have medical applications involving the detection and monitoring of certain chromogenic diseases or disorders such as bilirubuin infant jaundice. The Company defines chromogenic diseases or disorders as those diagnosed or monitored by the coloration of the human skin, tissue or fluid being affected. In this regard, the Company has received Food and Drug Administration (FDA) clearance for commercial marketing of its medical device for detection and monitoring of bilirubin infant jaundice. Other medical applications will require additional clinical trials and FDA clearance. The Company's technologies and intellectual properties also have other applications, including the scientific color measurement and classification of human skin, certain color-sensitive consumer products, and in determining the color compatibility of such skin and product color classification for use in a variety of industries including the cosmetic, beauty-aid and fashion industries. Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business which may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, the availability of any needed financing, the Company's ability to implement its long range business plan for various applications for its technologies, the impact of competition, the obtaining of further regulatory clearances applicable to proposed new applications of the Company's technology, management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, including those set forth in its annual report on Form 10-K for the year ended December 31, 1997. SOURCE Chromatics Color Sciences International, Inc.